Treatment with 10 or 20 mg/ml Elo resulted in full saturation of more than 80% of SLAMF7 binding sites on CD38+ myeloma cells and consistently achieved Elo serum concentration of more than 70 ug/ml in patients, with peak concentrations of up to 1 mg/ml in serum (48). Here, CD38 is linked to plasma cell myeloma.